Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.

Leukemia - 1 Sept 2022

Jahn Nikolaus, Jahn Ekaterina, Saadati Maral, Bullinger Lars, Larson Richard A, Ottone Tiziana, Amadori Sergio, Prior Thomas W, Brandwein Joseph M, Appelbaum Frederick R, Medeiros Bruno C, Tallman Martin S, Ehninger Gerhard, Heuser Michael, Ganser Arnold, Pallaud Celine, Gathmann Insa, Krzykalla Julia, Benner Axel, Bloomfield Clara D, Thiede Christian, Stone Richard M, Döhner Hartmut, Döhner Konstanze

Abstract excerpt

The aim of this study was to characterize the mutational landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the randomized CALGB 10603/RATIFY trial evaluating intensive chemotherapy plus the multi-kinase inhibitor midostaurin versus placebo. We performed sequencing of 262 genes in 475 patients: mutations occurring concurrently with the FLT3-mutation were most frequent in NPM1...

Topics

Genomics
Humans
Leukemia, Myeloid, Acute
Mutation
Nucleophosmin
Prognosis
fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 35922444
DOI: 10.1038/s41375-022-01650-w
PMCID: PMC9417991

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-35922444-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.PMID 35922444Read ↗

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsSemantic proximity Read ↗

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.Semantic proximity Read ↗

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.Semantic proximity Read ↗

Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.Semantic proximity Read ↗

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutationsSemantic proximity Read ↗

Frequency and Impact of Somatic Co-occurring Mutations on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Multicenter Registry Analysis on Behalf of the EBMT ALWPSemantic proximity Read ↗

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.Semantic proximity Read ↗

Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.Semantic proximity Read ↗

Integrative Genomic and Immune Profiling to Identify and Characterize High-Risk Subgroups in Acute Myeloid Leukemia: Development of a 20-Gene Predictive Signature and Its Clinical Implications.Semantic proximity Read ↗

Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3.Semantic proximity Read ↗

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.Semantic proximity Read ↗

Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.